BIOMAT Database Logo BIOMAT Database Logo

Comparative study of in vitro antimicrobial activity and human pharmacokinetics of dibekacin and tobramycin. 1982

L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D003982 Dibekacin Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties. Dideoxykanamycin B,3',4'-Dideoxykanamycin B,Dibekacin Sulfate,Dibekacin Sulphate,Dideoxykanamycine,Orbicin,3',4' Dideoxykanamycin B,B, 3',4'-Dideoxykanamycin,Sulfate, Dibekacin,Sulphate, Dibekacin
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria

Related Publications

L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
[Comparative in vitro activity of dibekacin, gentamicin and tobramycin on 617 bacterial strains].
November 1982, La Nouvelle presse medicale,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
Comparative low-dose nephrotoxicities of dibekacin, gentamicin, and tobramycin.
April 1982, The Journal of antimicrobial chemotherapy,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
[Evaluation of the ototoxicity of aminoglycosides. Comparative study of dibekacin, gentamicin and tobramycin].
November 1982, La Nouvelle presse medicale,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
[Functional, histological, biochemical renal modifications. Comparative study of dibekacin, gentamicin, tobramycin, netilmicin and amikacin].
November 1982, La Nouvelle presse medicale,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
A comparative study on the ototoxicity of dibekacin and tobramycin administered by intravenous infusion.
October 1979, The Japanese journal of antibiotics,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
[Dibekacin--a novel aminoglycoside antibioticl. Antimicrobial activity and parallel resistance in vitro].
January 1979, Arzneimittel-Forschung,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
Comparative pharmacokinetics of tobramycin and gentamicin.
January 1973, Clinical pharmacology and therapeutics,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
[In-vitro antimicrobial activity of 2 aminoglycoside antibiotics: tobramycin and gentamycin].
March 1979, Bollettino della Societa italiana di biologia sperimentale,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
[Comparative study of the in vitro activity of dibekacin, piperacillin, cefotaxime and cefuroxime on gram-negative bacteria].
January 1983, Giornale di batteriologia, virologia ed immunologia,
L Verbist, and T B Tjandramaga, and A Mullie, and A Van Hecken, and R Verbesselt, and P J De Schepper
Antimicrobial activity of dactimicin in vitro compared with that of dibekacin, netilmicin, sisomicin and micronomicin.
January 1989, Drugs under experimental and clinical research,
Copied contents to your clipboard!